{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:12:16Z","timestamp":1780362736751,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11307-019-01329-2","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T20:28:57Z","timestamp":1551990537000},"page":"1192-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-8686","authenticated-orcid":false,"given":"Marius E.","family":"Mayerhoefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Staudenherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Dolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"publisher","unstructured":"Mettler J, M\u00fcller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C (2018) Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. \nhttps:\/\/doi.org\/10.2967\/jnumed.118.210047","DOI":"10.2967\/jnumed.118.210047"},{"key":"1329_CR2","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34:3618\u20133626","journal-title":"J Clin Oncol"},{"key":"1329_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, Wrench D, Barrington SF (2016) Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 43:1209\u20131219","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1329_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","volume":"126","author":"L Ceriani","year":"2015","unstructured":"Ceriani L, Martelli M, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PWM, Zucca E (2015) Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 126:950\u2013956","journal-title":"Blood"},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00259-017-3776-3","volume":"44","author":"S Becker","year":"2017","unstructured":"Becker S, Vermeulin T, Cottereau AS, Boissel N, Vera P, Lepretre S (2017) Predictive value of 18F-FDG PET\/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. Eur J Nucl Med Mol Imaging 44:2034\u20132041","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1329_CR6","doi-asserted-by":"publisher","unstructured":"Albano D, Bosio G, Camoni L et al (2018) Prognostic role of baseline 18F-FDG PET\/CT parameters in MALT lymphoma. Hematol Oncol. \nhttps:\/\/doi.org\/10.1002\/hon.2563","DOI":"10.1002\/hon.2563"},{"key":"1329_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/bloodadvances.2017013698","volume":"2","author":"S Qi","year":"2018","unstructured":"Qi S, Huang MY, Yang Y, Sch\u00f6der H, Teckie S, Noy A, Chau K, Yahalom J (2018) Uptake of [18F] fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. Blood Adv 2:649\u2013655","journal-title":"Blood Adv"},{"key":"1329_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/MNM.0000000000000579","volume":"37","author":"JP Hwang","year":"2016","unstructured":"Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM (2016) Prognostic value of SUVmax measured by pretreatment 18F-FDG PET\/CT in patients with primary gastric lymphoma. Nucl Med Commun 37:1267\u20131272","journal-title":"Nucl Med Commun"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048\u20133058","journal-title":"J Clin Oncol"},{"key":"1329_CR10","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi A, Martinelli G, Thi\u00e9blemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741\u20132745","journal-title":"Blood"},{"key":"1329_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257\u20131260","journal-title":"Leuk Lymphoma"},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ, European Association of Nuclear Medicine (EANM) (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1329_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, Soussan M, Frouin F, Frouin V, Buvat I (2018) A postreconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med 59:1321\u20131328","journal-title":"J Nucl Med"},{"key":"1329_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2967\/jnumed.113.123646","volume":"55","author":"M Eiber","year":"2014","unstructured":"Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Furst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ (2014) Performance of whole-body integrated 18F-FDG PET\/MR in comparison to PET\/CT for evaluation of malignant bone lesions. J Nucl Med 55:191\u2013197","journal-title":"J Nucl Med"},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11307-017-1044-3","volume":"19","author":"X Wu","year":"2017","unstructured":"Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL (2017) The association between liver and tumor [18F] FDG uptake in patients with diffuse large B cell lymphoma during chemotherapy. Mol Imaging Biol 19:787\u2013794","journal-title":"Mol Imaging Biol"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21330","volume":"66","author":"M Raderer","year":"2016","unstructured":"Raderer M, Kiesewetter B, Ferreri AJ (2016) Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 66:153\u2013171","journal-title":"CA Cancer J Clin"},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zach\u00e9e P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C (2017) Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol 35:1905\u20131912","journal-title":"J Clin Oncol"},{"key":"1329_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL (2018) Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy. Front Oncol 8:163","journal-title":"Front Oncol"},{"key":"1329_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clml.2018.05.009","volume":"18","author":"L Falchi","year":"2018","unstructured":"Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P (2018) An evidence-based review of anti-CD20 antibody-containing regimens for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 18:508\u2013518","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1329_CR20","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","volume":"36","author":"Q Shi","year":"2018","unstructured":"Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR (2018) Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol 36:2593\u20132602","journal-title":"J Clin Oncol"},{"key":"1329_CR21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/RLU.0000000000001718","volume":"42","author":"G\u00f3mez Le\u00f3n N, Delgado-Bolton RC, Del Campo Del Val L, et al","year":"2017","unstructured":"G\u00f3mez Le\u00f3n N, Delgado-Bolton RC, Del Campo Del Val L, et al (2017) Multicenter comparison of contrast-enhanced FDG PET\/CT and 64-slice multi-detector-row CT for initial staging and response evaluation at the end of treatment in patients with lymphoma. Clin Nucl Med 42:595\u2013602","journal-title":"Clin Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-019-01329-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:15:34Z","timestamp":1583453734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-019-01329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s11307-019-01329-2","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"7 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Marius E. Mayerhoefer received honoraria for lectures as well as research support (not related to the present study) from Siemens Healthineers.Barbara Kiesewetter and Markus Raderer received honoraria for lectures from Celgene, Ipsen, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}